Immunogenic cell death-related risk signature for tumor microenvironment profiling and prognostic prediction in colorectal cancer

  • 0Colorectal Surgery, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China.

|

|

Summary

This summary is machine-generated.

This study identifies three immunogenic cell death (ICD) genes (CLMP, NRP1, PLEKHO1) that predict colorectal cancer (CRC) survival and chemotherapy response, offering new prognostic tools.

Area Of Science

  • Oncology
  • Immunology
  • Genetics

Background

  • Immunogenic cell death (ICD) influences the tumor immune microenvironment and adaptive immunity.
  • The clinical role of ICD-associated genes in colorectal cancer (CRC) is not well understood.

Purpose Of The Study

  • To identify ICD-related genes and develop a prognostic model for colorectal cancer (CRC).
  • To investigate the association between the developed risk score and immune cell infiltration and chemotherapy sensitivity in CRC.

Main Methods

  • Weighted gene co-expression network analysis (WGCNA) and LASSO regression were used to identify key ICD genes and construct a risk score (ICDRS).
  • ESTIMATE, Gene Set Enrichment Analysis (GSEA), and the oncoPredict package were employed to assess immune infiltration and drug sensitivity.
  • In vitro experiments validated gene expression and functional roles.

Main Results

  • Three prognostic genes (CLMP, Neuropilin-1 (NRP1), and PLEKHO1) were identified and used to build the ICDRS.
  • A high ICDRS independently predicted poorer overall survival (OS) in CRC patients and correlated with increased immune cell infiltration.
  • The ICDRS showed significant correlation with sensitivity to chemotherapeutic drugs, and NRP1 promoted CRC cell proliferation, migration, and invasion.

Conclusions

  • The ICD-related risk score (ICDRS) serves as a reliable prognostic predictor for colorectal cancer (CRC).
  • The ICDRS has potential utility in guiding personalized chemotherapy strategies for CRC patients.
  • CLMP, NRP1, and PLEKHO1 are differentially expressed in CRC and NRP1 plays a functional role in CRC progression.